AzTrials
AzTrials

Systemic Sclerosis Associated GIT VasculopathyNCT07171437

Assessment of GIT Vasculopathy in SSc and Its Multisystem Correlations

An observational study of Systemic Sclerosis Associated GIT Vasculopathy, run by Esraa Moustafa Mohammed at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Evaluation of splanchnic vasculature, including arterial blood flow using Doppler ultrasound in patients with systemic sclerosis compared to healthy subjects. Correlation of Doppler findings of splanchnic vessels with GIT manifestations. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Doppler ultra sound
Type of treatment
Medical device
How many people
74 participants
Where
1 siteEgypt
Study dates
1 Oct 2025to Nov 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients aged 18 years or older classified as systemic sclerosis (SSc) according to ACR/EULAR 2013 classification criteria subject to in- hospital care due to SSc at Assiut University Hospital will be undergoing to clinical assessment, laboratory assessment and imaging

Who may be able to join

  • Adult patients aged 18 years or older.
  • Patients classified as systemic sclerosis (SSc) according to ACR/EULAR 2013 classification criteria.
  • Patients who consented to undergo Doppler ultrasound (DUS) assessment of the splanchnic vessels.

Who cannot join

  • Patients younger than 18 years old.
  • Pregnancy or lactation.
  • Patients with overlapping autoimmune diseases (e.g., lupus, rheumatoid arthritis).
  • Patients with known gastrointestinal disorders not related to systemic sclerosis (e.g., inflammatory bowel disease, celiac disease).
  • Patients with a history of major gastrointestinal surgery (e.g., bowel resection).
  • Patients with diabetes mellitus (due to its independent effects on vascular flow).
  • Presence of severe comorbidities (e.g., end-stage renal disease, decompensated heart failure).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Esraa Moustafa Mohammed, Specialist of Rheumatology contact

+201094335622

moustafaesraa0@gmail.com

Nihal Ahmed Fathy, Professor of Rheumatology contact

+201005364739

nfathy@yahoo.com,

Egypt1 site
  • Assiut University, Assiut, 71111

    Asyut

    Esraa Moustafa Mohammed, Specialist of Rheumatology, +201094335622, moustafaesraa0@gmail.com

Other trials in Egypt

About this study

Official title: Assessment of Gastrointestinal Vasculopathy in Systemic Sclerosis and Its Multisystem Correlations

  • Evaluation of splanchnic vasculature, including arterial blood flow using Doppler ultrasound in patients with systemic sclerosis compared to healthy subjects.
  • Correlation of Doppler findings of splanchnic vessels with GIT manifestations.
  • Correlation of Doppler findings of splanchnic vessels with macrovascular affection (chest, cardiac, and renal), microvascular involvement (capillaroscopy findings), and autoantibodies (anti-SCL70 antibody and anti-centromere antibody).
Read the detailed description

Systemic sclerosis (SSc) is a rare, chronic autoimmune disease characterized by a complex pathophysiology involving humoral and cellular immunity, endothelial cells, and fibroblasts, leading to widespread vascular injury and excessive deposition of collagen fibers in the skin and major internal organs.

Vasculopathy is one of the main hallmarks of SSc; an early and accelerated atherosclerosis has been described in SSc; the underlying vasculopathy leads to significant impairment of blood flow due to the combined macro- and microvascular involvement. This vascular pathology may involve major organs such as the lungs, heart, GIT, and kidneys. While clinical observations and basic studies suggest that microvascular vasculopathy is of paramount importance throughout all the phases of SSc, increasing evidence suggests that macrovascular involvement also plays a critical role in the disease. Gastrointestinal (GI) involvement is highly prevalent, affecting up to 90% of SSc patients. It often remains subclinical until significant tissue damage has occurred, due to the progression of vasculopathy and fibrosis. Once symptoms develop, SSc-related GI involvement significantly worsens morbidity and mortality, patients frequently suffer marked emotional and social burdens, and advanced GI disease correlates with a more than twofold increased risk of death. The GI manifestations of SSc are heterogeneous, with possible involvement at any level, from the oral cavity down to the esophagus, stomach, small and large intestines, as well as the liver and pancreas, causing several clinical manifestations.

Upper GI involvement may result in esophageal dysmotility, gastroesophageal reflux disease (GERD), gastroparesis, GI bleeding due to esophagitis, esophageal or gastric ulcers, or gastric antral vascular ectasia (GAVE). Moreover, esophageal dysfunction has been closely linked to interstitial lung disease, indicating a possible pathogenic relationship. Lower GI-tract involvement (i.e., small intestine, large intestine, and anorectal) can also be severe, with complications including small intestinal bacterial overgrowth (SIBO), intestinal pseudo-obstruction, intestinal pneumatosis, and fecal incontinence. Impaired GI perfusion may be linked to motility disorders, which are key contributors to stasis, bowel dilation, bacterial overgrowth, malabsorption, weight loss, and ultimately reduced survival rate.

Early recognition of GI involvement is essential for symptom control and the prevention of complications. However, the diagnosis of GI involvement is challenging because it is often delayed by the lack of signs and symptoms early in the disease. Moreover, several diagnostic investigations that are useful in defining GI involvement are either invasive, expensive, or not very informative.

The involvement of the splanchnic circulation has only recently gained attention, despite vasculopathy being a systemic feature of SSc.

The vasculature of the GI tract can be evaluated noninvasively using abdominal Doppler ultrasound (DUS), a valuable tool that enables assessment of the GI vasculature and associated structures, including extra-intestinal features and splanchnic vessels. DUS measures signals from visceral vessels supplying the GI tract and evaluates the celiac trunk (CT), superior mesenteric artery (SMA), and inferior mesenteric artery (IMA) using pulsed Doppler scanning. It provides several quantifiable hemodynamic parameters, such as peak systolic, mean, and end-diastolic velocities, resistive index (RI), pulsatility index (PI), and blood flow volume.

Few studies have specifically investigated vascular abnormalities in the small and large intestines, particularly those affecting the superior and inferior mesenteric arteries. Among them, only one study has examined the correlation between DUS parameters of these mesenteric arteries and the involvement of other organs.

Being tested
Doppler ultra sound

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Doppler ultra soundDevice

    • Doppler Ultrasound (DUS) To evaluate the abdominal aorta and the 3 main splanchnic vessels: Celiac Trunk (CT) Superior Mesenteric Artery (SMA) Inferior Mesenteric Artery (IMA) An ultrasound examination will be performed after a fasting period of at least 8 hours by a single operator blinded to clinical features. For abdominal vessels, the following parameters were measured: caliber, thickness, echogenicity, peak systolic velocity (PSV), end diastolic velocity (EDV), reverse velocity (RV), mean velocity (MV), resistive index (RI), and pulsatility index (PI).
Study groups in NCT07171437
Study groupRoleWhat they receive
1-Study group will be undergoing to general assessment, laboratory assessment and imagingNot described
Receives: Device: Doppler ultra sound
Study group (37 patients) and control group (37 participants)Study group will be undergoing clinical assessment including
Receives: Device: Doppler ultra sound

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of splanchnic vasculature, including arterial blood flow by Doppler ultrasound in SSc patients compared to healthy controls, and its correlation with GIT manifestations.

    Measured: baseline

Secondary outcomes (1)
  1. Correlation of Doppler findings of splanchnic vessels with macrovascular affection (chest, cardiac, and renal), microvascular involvement (capillaroscopy findings), and autoantibodies (anti-SCL70 antibody and anti-centromere antibody).

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2025
  2. Study start1 Oct 2025 (estimated)
  3. Primary completionOct 2026 (estimated)
  4. Study completionNov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
74 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07171437
Sponsor's protocol ID
GIT Vasculopathy in SSc
Status last verified
Sep 2025
First submitted
6 Sep 2025
Last updated
12 Sep 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Bandini G, Monami M, Ciuti G, Mercatelli P, Lo Cricchio A, De Santis MC, Bonomi F, Bellando Randone S, Campochiaro C, El Aoufy K, Ruaro B, Giuggioli D, Hughes M, McMahan ZH, Benfaremo D, Moroncini G, Maconi G, Accogli E, Dagna L, Matucci Cerinic M, Moggi Pignone A. Doppler ultrasound, a noninvasive tool for the study of mesenteric arterial flow in systemic sclerosis: a cross-sectional study of a patient cohort with review and meta-analysis of the literature. Intern Emerg Med. 2025 Mar;20(2):381-394. doi: 10.1007/s11739-024-03783-5. Epub 2024 Oct 16.

    PubMed 39412608
  • Bandini G, Campochiaro C, Ciuti G, Baccellieri D, Ardita V, Bellando Randone S, El Aoufy K, Giuggioli D, Orlandi M, Dagna L, Chiesa R, Matucci Cerinic M, Moggi Pignone A. Doppler ultrasound unveils splanchnic arteries ischemia allowing early successful revascularization in symptomatic systemic sclerosis patients. Eur J Intern Med. 2025 May;135:126-129. doi: 10.1016/j.ejim.2025.03.019. Epub 2025 Mar 25.

    PubMed 40140335
  • McMahan Z, Pandolfino J, Perlman H, Del Galdo F, Hinchcliff M. Gastrointestinal disease in systemic sclerosis: the neglected organ system? Curr Opin Rheumatol. 2024 Nov 1;36(6):374-378. doi: 10.1097/BOR.0000000000001052. Epub 2024 Aug 28.

    PubMed 39193877
  • Keringer P, Kovacs KT, Nagy G, Agoston-Szabo A, Filipanits K, Kiss FI, Szabo A, Kumanovics G. Patient-reported gastrointestinal involvement is associated with reduced quality of life and disability in systemic sclerosis. J Scleroderma Relat Disord. 2025 Jun 5;10(3):597-605. doi: 10.1177/23971983251345284. eCollection 2025 Oct.

    PubMed 40488215

Questions about this trial

What is this clinical trial studying?

An observational study of Systemic Sclerosis Associated GIT Vasculopathy, run by Esraa Moustafa Mohammed at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Esraa Moustafa Mohammed, Specialist of Rheumatology (+201094335622, moustafaesraa0@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of splanchnic vasculature, including arterial blood flow by Doppler ultrasound in SSc patients compared to healthy controls, and its correlation with GIT manifestations. (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07171437, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in